Elevation Oncology, Inc.: debt financing — Elevation Oncology to voluntarily prepay $32.2M term loan with K2HV

Elevation Oncology, Inc.

Principal of $30.0M plus prepayment fee of $300K, final payment $1.935M, and accrued interest.
Expected prepayment date on or about May 3, 2025.
Loan agreement originally signed July 27, 2022, amended March 1, 2024.
Company delivered written notice of election to prepay all outstanding term loan.

item 2.04

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.85

Elevation Oncology, Inc. faced acceleration on term loan of $30.0 million with K2 HealthVentures LLC.

Instrument: term loan
Principal: $30.0 million
Counterparty: K2 HealthVentures LLC
Event: acceleration

Exact text from the filing

Ankura Trust Company, LLC, as collateral agent. Pursuant to the Loan Agreement, the Lenders provided a term loan to the Company in the aggregate original principal amount of $30.0 million (the “Term Loan”). Under the Loan Agreement, the Company has the option to prepay all, but not less than all, of the Term Loan, provided that the Company pays on the date of such

View on SEC.gov

Browse all debt financings →

Source: SEC EDGAR

accession 0001558370-25-004491

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.